GlassScriptPhysician profile
Robert M Lazar
NPI 1730164179
$9,070.66
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,670 · 2020: $559 · 2021: $1,246 · 2022: $1,144 · 2023: $451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $451.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $451.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharming Healthcare, INC. | $3,913.29 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,022.23 | 2019-2023 | Xifaxan |
| Abbvie INC. | $821.50 | 2019-2023 | |
| Ferring Pharmaceuticals INC. | $491.03 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $366.32 | 2019-2022 | |
| Qol Medical, LLC | $346.97 | 2019-2022 | |
| Nestle Healthcare Nutrition INC. | $324.60 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $262.46 | 2021 | |
| Braintree Laboratories, INC. | $249.45 | 2019-2022 | |
| Ironwood Pharmaceuticals, INC | $218.37 | 2019-2023 | Linzess |
| Janssen Biotech, INC. | $208.52 | 2019-2023 | Stelara |
| Celgene Corporation | $206.79 | 2021-2023 | Zeposia |
| Daiichi Sankyo INC. | $168.85 | 2019-2023 | Injectafer |
| Merck Sharp & Dohme LLC | $114.28 | 2019-2021 | |
| Intercept Pharmaceuticals, INC. | $74.43 | 2022-2023 | Ocaliva |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $69.32 | 2023 | Ibsrela |
| Allergan, INC. | $60.39 | 2019 | |
| Redhill Biopharma INC. | $42.32 | 2020-2022 | |
| Regeneron Healthcare Solutions, INC. | $41.17 | 2023 | Dupixent |
| Vivus LLC | $20.56 | 2022 | |
| Ucb, INC. | $20.44 | 2019 | |
| Shire North American Group INC | $16.03 | 2019 | |
| Alfasigma USA, INC. | $11.34 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Lazar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.